Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab and Anakinra in COVID-19 Hyper-inflammation
NCT04324021Phase 3Terminated
- Sponsor
- Sobi
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 3 trial of emapalumab, anakinra in coronavirus disease 2019 (COVID-19), sponsored by Sobi. Started Apr 2020; status: terminated.
02
Drugs
emapalumabanakinra
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04324021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324021.